Firuz joined Regulus Therapeutics in 2019.  He has over 38 years of experience in the peptide and oligonucleotide industry. As head of CMC, Firuz oversees the inventory of raw materials (Amidites), the manufacturing of drug substance and drug product, as well as packaging and labeling for clinical trials. Over his long career, Firuz has held a variety of positions from bench chemist to vice‐president of manufacturing. Previously, he held a position at Bachem Inc. as a senior director of client programs and was responsible for all supply of oligonucleotides.  At Sarepta Therapeutics, as a senior director of manufacturing science & technology, he worked closely with the regulatory department for CMC submission of follow-on exons to gain approval by the U.S. Food and Drug Administration of Exondys 51 (oligonucleotide) for Duchenne Muscular Dystrophy. Firuz holds an M.S. in synthetic organic chemistry.